Related Experiment Video
Updated: Jul 16, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
Malignant mesothelioma
Bruce W S Robinson1, Arthur W Musk, Richard A Lake
1Tumour Immunology Group, School of Medicine and Pharmacology, University of Western Australia, Australia. bwsrobin@cyllene.uwa.edu.au
Abstract:
Malignant mesothelioma is an aggressive, treatment-resistant tumour, which is increasing in frequency throughout the world. Although the main risk factor is asbestos exposure, a virus, simian virus 40 (SV40), could have a role. Mesothelioma has an unusual molecular pathology with loss of tumour suppressor genes being the predominant pattern of lesions, especially the P16INK4A, and P14ARF, and NF2 genes, rather than the more common p53 and Rb tumour suppressor genes. Cytopathology of mesothelioma effusions or fine-needle aspirations are often sufficient to establish a diagnosis, but histopathology is also often required. Patients typically present with breathlessness and chest pain with pleural effusions. Median survival is now 12 months from diagnosis. Palliative chemotherapy is beneficial for mesothelioma patients with high performance status. The role of aggressive surgery remains controversial and growth factor receptor blockade is still unproven. Gene therapy and immunotherapy are used on an experimental basis only. Patterns identified from microarray studies could be useful for diagnosis as well as prognostication.
Insights
Malignant mesothelioma is an aggressive cancer linked to asbestos and potentially simian virus 40 (SV40). Its molecular pathology involves specific tumor suppressor gene loss, aiding diagnosis and prognostication.
Area of Science:
- Oncology
- Pathology
- Virology
Background:
- Malignant mesothelioma is an aggressive, increasingly frequent cancer.
- Asbestos exposure is the primary risk factor, with simian virus 40 (SV40) as a potential contributor.
- The disease presents with symptoms like breathlessness and chest pain, often with pleural effusions.
Purpose of the Study:
- To summarize the key aspects of malignant mesothelioma, including its etiology, pathology, diagnosis, and current treatment strategies.
- To highlight the unique molecular characteristics of mesothelioma.
- To discuss the potential role of novel diagnostic and prognostic tools.
Main Methods:
- Review of current literature on malignant mesothelioma.
- Analysis of cytopathological and histopathological diagnostic criteria.
- Examination of molecular pathology, focusing on tumor suppressor gene alterations.
- Consideration of microarray study findings for diagnosis and prognostication.
Main Results:
- Mesothelioma exhibits distinct molecular pathology, characterized by loss of P16INK4A, P14ARF, and NF2 tumor suppressor genes.
- Cytopathology and histopathology are crucial for diagnosis.
- Median survival is approximately 12 months post-diagnosis.
- Palliative chemotherapy benefits patients with good performance status.
Conclusions:
- Malignant mesothelioma requires a multi-faceted diagnostic approach.
- Understanding its unique molecular profile is key for diagnosis and prognostication.
- Further research into gene therapy, immunotherapy, and microarray patterns is warranted.
Related Concept Videos
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Renewal of Skin Epidermal Stem Cells
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Reticular Dermis
Reticular Layer
Underlying the papillary layer is the much thicker reticular layer, composed of dense, irregular connective...
Healing II: Complications

